This proposed five-year study will focus on whether the addition of providing XR-NTX
treatment at a patients' place of residence will increase adherence and thus efficacy of the
medication.Following initial screening, informed consent, and medical examination,
pre-release prisoners at each facility will be block randomized (N=240) within gender to
either: Condition 1. XR-NTX-OTx (n=120): One injection of XR-NTX in prison, followed by six
monthly injections post-release in the community at an opioid treatment program; or Condition
2. XR-NTX+MMTx (n=120): One injection of XR-NTX in prison, followed by six monthly injections
post-release in the community at the patient's place of residence.